Edwards R, Kanematsu M, Greenwood D
Department of Microbiology, University Hospital, Queen's Medical Centre, Nottingham, UK.
J Antimicrob Chemother. 1988 Dec;22(6):885-90. doi: 10.1093/jac/22.6.885.
The activity of lomefloxacin and norfloxacin against 681 bacterial strains, including 520 strains isolated from infected urine was assessed in vitro. All strains were tested in two inocula and the susceptibility of urinary isolates was evaluated at three pH levels. Lomefloxacin displayed a broad spectrum of antibacterial activity which was similar to that of norfloxacin and which was independent of inoculum size. Good activity was shown for lomefloxacin against all Gram-negative urinary pathogens: strains of Pseudomonas spp and nalidixic acid-resistant enterobacteria were the least susceptible, indicating a degree of cross resistance between newer quinolones and nalidixic acid. Lomefloxacin generally showed more modest activity against Gram-positive cocci and bacteroides than against enterobacteria. Under the acidic conditions that commonly prevail in urine the activity of both compounds against Gram-negative urinary pathogens was markedly reduced, whereas strains of Gram-positive cocci were only minimally affected.
对洛美沙星和诺氟沙星针对681株细菌(包括从感染尿液中分离出的520株菌株)的体外活性进行了评估。所有菌株均以两种接种量进行测试,并在三个pH水平下评估尿液分离株的敏感性。洛美沙星显示出广谱抗菌活性,与诺氟沙星相似,且与接种量大小无关。洛美沙星对所有革兰氏阴性尿路病原体均表现出良好活性:铜绿假单胞菌菌株和耐萘啶酸肠杆菌对其最不敏感,表明新型喹诺酮类药物与萘啶酸之间存在一定程度的交叉耐药性。洛美沙星对革兰氏阳性球菌和拟杆菌的活性通常比对肠杆菌的活性更弱。在尿液中普遍存在的酸性条件下,这两种化合物对革兰氏阴性尿路病原体的活性均显著降低,而革兰氏阳性球菌菌株仅受到轻微影响。